Putting secure labs in cities: universities seek to avoid PR problem now facing NIH.

Artville Restructuring in the biotechnology industry has eliminated bench research positions as the economy tests companies whose leaders still boast of their dedication to basic science. "The majority of these job reductions were concentrated in the discovery research area and primarily in biology sciences," reads a typical layoff announcement, this one issued by OSI Pharmaceuticals of Melville, NY, in the autumn of 2002. OSI joins dozens of companies in deeming basic research an unaffordabl

Dishonesty insurance covers research fraud, US court rules.

US universities competing for plum designations as bioterror research centers.

Fee hikes and outsourcing considered to shrink application backlog in US and UK.

Courtesy of Charles River Laboratory Interpretations of the recent Canadian Supreme Court ruling denying Harvard University's OncoMouse patent protection in Canada depends on which side of the patent the interpreter is on. Harvard, in a statement, said the institution would appeal to the Canadian Parliament and predicted that the inability to get protection for genetically engineered mammals will hold back scientific research. Some bench scientists disagreed. "We do the experiments we want to

University, not researcher, faulted by court in misconduct case.

US universities resisting government attempts to control fundamental research.

Layoffs in 2002 left basic researchers reeling.

Concerns continue over US advisory panels' new make-up.

New US rules will be costly for labs and give government broad power to restrict research.

Public mouse sequence will cool the already waning gene patent frenzy.